论文部分内容阅读
目的分析研究中药联合化疗治疗晚期非小细胞肺癌的临床效果。方法选择2010年1月—2012年10月收治的126例晚期非小细胞肺癌患者作为研究对象,随机分为对照组和实验组各63例。对照组给予经皮锁骨下动脉化疗,实验组在对照组基础上给予扶正养阴汤治疗,两组均治疗6个疗程。比较两组化疗后6、12、18、24个月存活率、疗效及不良反应发生情况。计数资料采用χ2检验,等级资料采用秩和检验,P<0.05为差异有统计学意义。结果治疗后,实验组总有效率为58.7%,与对照组的39.7%比较差异有统计学意义(P<0.05)。实验组6、12、18、24个月存活率分别为79.4%、61.9%、49.2%、34.9%;明显高于对照组的63.5%、42.9%、31.7%、19.0%,两组间差异均有统计学意义(均P<0.05)。两组患者化疗后均出现不同程度的不良反应,实验组不良反应程度明显优于对照组,差异有统计学意义(P<0.05)。结论中药联合化疗治疗晚期非小细胞肺癌疗效显著,值得临床进一步推广。
Objective To analyze the clinical effect of traditional Chinese medicine combined with chemotherapy in the treatment of advanced non-small cell lung cancer. Methods One hundred and twenty-six patients with advanced non-small cell lung cancer who were admitted from January 2010 to October 2012 were randomly divided into control group and experimental group with 63 cases. The control group was given percutaneous subclavian artery chemotherapy. The experimental group was treated with Fuzheng Yangyin Decoction on the basis of the control group. Both groups were treated for 6 courses. The survival rate, curative effect, and incidence of adverse reactions at 6, 12, 18, and 24 months after chemotherapy were compared. Count data using χ2 test, rank data using rank sum test, P <0.05 was considered statistically significant. Results After treatment, the total effective rate was 58.7% in the experimental group, and there was a statistically significant difference (39.7%) from the control group (P<0.05). The survival rates of the experimental group at 6, 12, 18, and 24 months were 79.4%, 61.9%, 49.2%, and 34.9%, respectively; these were significantly higher than the 63.5%, 42.9%, 31.7%, and 19.0% of the control group. Statistically significant (all P<0.05). Both groups of patients had different degrees of adverse reactions after chemotherapy. The degree of adverse reactions in the experimental group was significantly better than that in the control group, and the difference was statistically significant (P<0.05). Conclusion Chinese medicine combined with chemotherapy is effective in the treatment of advanced non-small cell lung cancer, and it is worthy of further promotion in clinic.